Our Services
Medical Information
Helpful Resources
Published on: 5/21/2026
Biologics such as omalizumab target IgE and inflammatory cytokines to calm the overactive immune response that drives chronic spontaneous urticaria. This precision approach can reduce welts and itching and often allows patients to taper off high-dose antihistamines and steroids when standard therapies are insufficient.
There are several important considerations including candidacy criteria, dosing schedules, efficacy timelines and safety monitoring that could affect your next steps in care; see below for complete details.
Chronic hives (urticaria) can be more than a fleeting nuisance. For many people, daily life is disrupted by itching, swelling and visible welts on the skin. Traditional treatments like antihistamines and corticosteroids help most patients, but up to 30% still have persistent symptoms. In recent years, biologics for hives have emerged as a powerful new option—targeting the immune system at the molecular level to calm the skin's overactive response.
Hives are red, itchy bumps on the skin caused by the release of histamine and other inflammatory mediators from mast cells. In chronic spontaneous urticaria (CSU):
Over time, this constant immune activity damages the skin barrier and sets up a cycle of itching and swelling.
Most guidelines start with second-generation antihistamines. If hives persist, doses may be increased or combined with:
While helpful, these approaches can have drawbacks:
That's where biologics for hives targets skin come into play—offering precision rather than broad-spectrum immune suppression.
Biologics are medicines made from living organisms or their components. They include:
Unlike small-molecule drugs, biologics:
In CSU, biologics interrupt the chain of events that leads to mast cell activation and histamine release.
The first and most widely used biologic for chronic hives is omalizumab:
By tackling IgE at its source, omalizumab helps to normalize the skin's response:
Emerging biologics are exploring additional targets:
Each new therapy represents a chance to fine-tune treatment based on an individual's immune profile.
Generally, biologics are considered when:
Your doctor will assess:
Biologics are administered under medical supervision, usually as a subcutaneous injection every 2–4 weeks.
Clinical trials of omalizumab in CSU have shown:
Safety profile:
As new biologics emerge, ongoing studies will clarify long-term safety and how they compare head-to-head.
By targeting immune pathways, biologics may also:
Researchers are exploring:
The goal is a world where hives are not only manageable but predictable—and where treatments are tailored to each person's unique immune system.
If you're struggling with chronic hives that haven't responded to standard therapies, consider:
Always speak to a healthcare professional before starting or changing any treatment. Hives can sometimes signal more serious conditions, and rapid swelling around the face or throat requires immediate medical attention.
Remember: While biologics for hives targets skin offer a promising path forward, every patient's journey is different. If you experience severe shortness of breath, dizziness, or facial swelling, seek emergency care right away. Otherwise, a thoughtful conversation with your doctor is the best way to decide if biologic therapy is right for you.
(References)
* Maurer M, Giménez-Arnau AM, Sussman G, Khan DA, Kaplan A, Weller K, Metz M. Biologics in chronic urticaria: practical considerations and current challenges. J Allergy Clin Immunol Pract. 2021 Jul;9(7):2628-2638.e1. doi: 10.1016/j.jacip.2021.03.024. Epub 2021 Mar 27. PMID: 33785461.
* Wedi B, Khatu SS. Omalizumab: a targeted approach to chronic spontaneous urticaria. Curr Opin Allergy Clin Immunol. 2020 Aug;20(4):394-400. doi: 10.1097/ACI.0000000000000650. PMID: 32549429.
* Vangipuram R, Mirmirani M, Kim S, Hsu S, Goldenberg G. Dupilumab efficacy in chronic spontaneous urticaria: a systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2023 Apr;130(4):460-466.e1. doi: 10.1016/j.anai.2022.12.012. Epub 2022 Dec 17. PMID: 36535492.
* Chauhan P, Mahajan VK, Mehta KS. Ligelizumab: a novel anti-IgE antibody for the treatment of chronic spontaneous urticaria. Expert Rev Clin Immunol. 2021 Mar;17(3):215-224. doi: 10.1080/1744666X.2021.1894371. Epub 2021 Mar 4. PMID: 33621948.
* Saini SS, Kaplan A, Asero R, Biagioni R, Boccara D, Borkowski Z, Cherrez-Ojeda I, Fomina D, Gisondi P, Greiner W, Kourtis G, Larco JI, Larenas-Linnemann D, Lwin SM, Metz M, Micali G, Miossec P, Omalu C, O'Shea E, Radulescu L, Razzaq SM, Sanchez-Borges M, Schäkel K, Sforza E, Soliman N, Steiner R, Vena GA, Ward J, Wilson JD, Worm M, Zuberbier T, Maurer M. Targeted Biologic Therapies for Chronic Urticaria. J Invest Dermatol. 2023 Apr;143(4):618-626.e1. doi: 10.1016/j.jid.2022.09.020. Epub 2022 Oct 26. PMID: 36306915.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.